ESTRELLA IMMUNOPHARMA, INC. (ESLA) Shareholder Equity
- 2026-06-30: Common Stock, Value, IssuedUSD $4.36K; Additional Paid in Capital, Common StockUSD (m); Additional Paid in CapitalUSD $34.75M; Treasury Stock, ValueUSD $598.38K.
- 2026-03-31: Common Stock, Value, IssuedUSD $4.32K; Additional Paid in Capital, Common StockUSD (m); Additional Paid in CapitalUSD $34.61M; Treasury Stock, ValueUSD $598.38K.
- 2025-12-31: Common Stock, Value, IssuedUSD $3.85K; Additional Paid in Capital, Common StockUSD (m); Additional Paid in CapitalUSD $27.22M; Treasury Stock, ValueUSD $598.38K.
- 2025-09-30: Common Stock, Value, IssuedUSD $3.83K; Additional Paid in Capital, Common StockUSD (m); Additional Paid in CapitalUSD $27.14M; Treasury Stock, ValueUSD $598.38K.
ESTRELLA IMMUNOPHARMA, INC. Shareholder Equity
Filed components and totals, with each concept and unit kept separate. Components can overlap; they are not added together. Missing disclosures remain (m). Original concept pages retain their detailed breakdowns and history.
| Period end | Common Stock, Value, Issued USD | Additional Paid in Capital, Common Stock USD | Additional Paid in Capital USD | Treasury Stock, Value USD | Retained Earnings (Accumulated Deficit) USD | Stockholders' Equity Attributable to Parent USD | Treasury Stock, Common, Shares shares | Treasury Stock, Value, Acquired, Cost Method USD | Adjustments to Additional Paid in Capital, Stock Issued, Issuance Costs USD | APIC, Share-based Payment Arrangement, Option, Increase for Cost Recognition USD | APIC, Share-based Payment Arrangement, Increase for Cost Recognition USD | Adjustments to Additional Paid in Capital, Increase in Carrying Amount of Redeemable Preferred Stock USD | Adjustments to Additional Paid in Capital, Stock Issued, Own-share Lending Arrangement, Issuance Costs USD | Adjustments to Additional Paid in Capital, Other USD |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $4.36K | (m) | $34.75M | $598.38K | $-41.59M | $-7.43M | 515.28K | (m) | (m) | 3 month · $145.30K | (m) | (m) | (m) | (m) |
| 2026-03-31 | $4.32K | (m) | $34.61M | $598.38K | $-39.28M | $-5.27M | 515.28K | (m) | (m) | 3 month · $146.71K | (m) | (m) | (m) | (m) |
| 2025-12-31 | $3.85K | (m) | $27.22M | $598.38K | $-36.99M | $-10.37M | 515.28K | 12 month · $29.46K | (m) | 12 month · $618.97K | (m) | (m) | (m) | (m) |
| 2025-09-30 | $3.83K | (m) | $27.14M | $598.38K | $-36.38M | $-9.84M | 515.28K | (m) | (m) | 3 month · $152.42K | (m) | (m) | (m) | (m) |
| 2025-06-30 | $3.76K | (m) | $26.08M | $598.38K | $-31.58M | $-6.09M | 515.28K | (m) | (m) | 3 month · $159.10K | (m) | (m) | (m) | (m) |
| 2025-03-31 | $3.67K | (m) | $24.80M | $598.38K | $-26.03M | $-1.83M | 515.28K | 3 month · $29.46K | (m) | 3 month · $159.09K | (m) | (m) | (m) | (m) |
| 2024-12-31 | $3.67K | (m) | $24.64M | $568.92K | $-23.93M | $143.73K | 486.98K | 6 month · $214.48K | (m) | 6 month · $432.26K | (m) | (m) | (m) | (m) |
| 2024-09-30 | $3.66K | (m) | $24.12M | $504.90K | $-22.88M | $746.29K | 431.72K | 3 month · $150.47K | (m) | (m) | (m) | (m) | (m) | (m) |
| 2024-06-30 | $3.66K | $24.12M | $24.12M | $354.44K | $-19.50M | $4.27M | 321.79K | 3 month · $270.35K 12 month · $354.44K | 12 month · $1.80M | 12 month · $1.19M | 12 month · $1.19M | (m) | (m) | (m) |
| 2024-03-31 | $3.66K | (m) | $24.12M | $84.09K | $-15.55M | $8.49M | 74.89K | 3 month · $84.09K | (m) | (m) | (m) | (m) | (m) | (m) |
| 2023-12-31 | $3.52K | (m) | $24.12M | (m) | $-15.08M | $9.05M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2023-09-30 | $3.52K | (m) | $24.12M | (m) | $-14.06M | $10.07M | (m) | (m) | 3 month · $1.80M | (m) | 3 month · $1.19M | (m) | (m) | (m) |
| 2023-09-29 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | 1 month · $467.12K | (m) | (m) |
| 2023-06-30 | $98.00 | $445.90K | $445.90K | (m) | $-12.19M | $-11.74M | 0.00 | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2023-03-31 | $142.00 | (m) | (m) | (m) | $-2.53M | $-9.11M | (m) | (m) | (m) | (m) | 3 month · $102.40K | (m) | (m) | (m) |
| 2022-12-31 | $142.00 | (m) | (m) | (m) | $-2.26M | $-6.48M | (m) | (m) | (m) | (m) | 3 month · $102.40K | (m) | (m) | (m) |
| 2022-09-30 | $142.00 | (m) | (m) | (m) | $-1.98M | $-3.82M | (m) | (m) | (m) | (m) | 3 month · $102.40K | (m) | (m) | (m) |
| 2022-06-30 | $142.00 | (m) | (m) | (m) | $-1.51M | $-1.04M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2022-03-31 | $142.00 | (m) | (m) | (m) | $-1.15M | $-1.15M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2021-12-31 | $142.00 | (m) | (m) | (m) | $-1.01M | $-1.01M | (m) | (m) | 12 month · $2.97M | (m) | (m) | (m) | 12 month · $-886.00K | 12 month · $-582.97K |
| 2021-09-30 | $142.00 | (m) | (m) | (m) | $-870.54K | $-870.39K | (m) | (m) | 3 month · $2.97M | (m) | (m) | (m) | 3 month · $-886.00K | 3 month · $-582.97K |
| 2021-07-19 | $145.00 | (m) | $0.00 | (m) | $-612.49K | $-612.35K | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2021-06-30 | (m) | (m) | (m) | (m) | (m) | $20.63K | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2021-03-31 | (m) | (m) | (m) | (m) | (m) | $24.18K | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2021-01-05 | (m) | (m) | (m) | (m) | (m) | $0.00 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Jasper Therapeutics, Inc. (JSPR) | United States | $0.020B | -0.37 |
| BioCardia, Inc. (BCDA) | United States | $0.016B | |
| DYADIC INTERNATIONAL INC (DYAI) | United States | $0.016B | |
| Passage BIO, Inc. (PASG) | United States | $0.015B | -0.43 |
| Pluri Inc. (PLUR) | $0.014B | ||
| INTENSITY THERAPEUTICS, INC. (INTS) | United States | $0.013B | -1.08 |
| BRAINSTORM CELL THERAPEUTICS INC. (BCLI) | United States | $0.013B | -1.05 |
| IN8BIO, INC. (INAB) | United States | $0.012B | -0.76 |
| Senti Biosciences Holdings, Inc. (SNTI) | United States | $0.011B | -0.70 |
| CEL SCI CORP (CVM) | United States | $0.030B | -0.81 |